Antares Pharma Announces Closing of Public Offering of Common Stock

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex: AIS) today announced the closing of its previously announced firm commitment underwritten public offering of 12,500,000 shares of the Company’s common stock at a purchase price of $1.60 per share.

The underwriters have exercised in full their over-allotment option to purchase an additional 1,875,000 shares of the Company’s common stock at a purchase price of $1.60 per share. The net proceeds to the Company are expected to be approximately $21.4 million, after deducting underwriting commissions and estimated offering expenses payable by the Company.

Oppenheimer & Co. Inc. acted as the sole bookrunner for the offering. ROTH Capital Partners and Ladenburg Thalmann Co. Inc. acted as financial advisers.

A copy of the prospectus supplement and accompanying prospectus may be obtained by sending a request to Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 300 Madison Avenue, 4^th Floor, New York, NY, 10017, Telephone number: [phone], Email: [e-mail].

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Antares Pharma

Antares Pharma focuses on self-injection pharmaceutical products and topical gel-based medicines. The Company's subcutaneous and intramuscular injection technology platforms include Vibex™ disposable pressure-assisted auto injectors, disposable multi-use pen injectors and Vision™ reusable needle-free injectors distributed as Tjet^® and Zomajet^® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. In the injector area, Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin^® human growth hormone (hGH) and a partnership with Ferring that includes Zomacton^® hGH. In the gel-based area, the Company's lead product candidate is Anturol^®, an oxybutynin ATD™ gel that is currently under review by the FDA for the treatment of OAB (overactive bladder). Antares also has a partnership with BioSante that includes LibiGel^® (transdermal testosterone gel) in Phase 3 clinical development for the treatment of female sexual dysfunction (FSD), and Elestrin^® (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and currently marketed in the U.S. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development and product commercialization activities in Minneapolis, Minnesota and Muttenz, Switzerland.